ValuEngine upgraded shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) from a strong sell rating to a sell rating in a research report sent to investors on Monday.

Other equities analysts also recently issued reports about the stock. Maxim Group raised shares of Pluristem Therapeutics from a hold rating to a buy rating and set a $2.00 price objective for the company in a report on Monday, June 19th. HC Wainwright set a $4.00 target price on shares of Pluristem Therapeutics and gave the company a buy rating in a research report on Thursday, August 17th. Finally, Zacks Investment Research cut shares of Pluristem Therapeutics from a hold rating to a sell rating in a research note on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Pluristem Therapeutics presently has an average rating of Hold and a consensus target price of $3.19.

Pluristem Therapeutics (PSTI) opened at 1.53 on Monday. The stock’s 50 day moving average price is $1.30 and its 200 day moving average price is $1.31. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $1.65. The company’s market capitalization is $149.13 million.

ILLEGAL ACTIVITY WARNING: “Pluristem Therapeutics, Inc. (PSTI) Upgraded to “Sell” at ValuEngine” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at

An institutional investor recently raised its position in Pluristem Therapeutics stock. Jane Street Group LLC lifted its holdings in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 62.4% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 108,830 shares of the biotechnology company’s stock after purchasing an additional 41,796 shares during the period. Jane Street Group LLC owned 0.11% of Pluristem Therapeutics worth $134,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Stock Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related stocks with our FREE daily email newsletter.